Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Clin J Am Soc Nephrol ; 4(6): 1097-101, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19470659

RESUMO

BACKGROUND AND OBJECTIVES: Published studies suggest that longer hemodialysis (HD) sessions are associated with improved morbidity and mortality, but few centers offer long sessions. The Western Infirmary renal unit has offered long overnight hemodialysis (LOH) (6 to 7 h) thrice weekly since 1998. The aim of this study was to describe patients who chose LOH and compare outcomes with patients on conventional hours (4 to 5 h) HD. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: Patients who ever had LOH for three or more consecutive sessions were identified (n = 146). Indices of urea reduction ratio (URR), anemia, hyperphosphatemia, and predialysis BP (BP) control in a subgroup of all patients on LOH for at least 1 yr since 2004 were compared with age, sex, and diabetes-matched controls undergoing conventional duration HD. RESULTS: The mean age at the time of starting LOH was 51.8 yr and 74.7% started with a functioning arteriovenous fistula. Median duration of continuous LOH was 1.6 yr. Of those no longer on LOH, only 33.3% reverted to conventional hours HD (mean duration LOH 2.2 yr). When comparing LOH and conventional HD cohorts, there was increased URR and mean hemoglobin with a trend toward lower mean erythropoietin index. There was a trend toward fewer phosphate binder tablets but no difference in mean serum phosphate, BP, or number of prescribed antihypertensive medicines. CONCLUSIONS: LOH is a well tolerated hemodialysis option, associated with improved URR and better control of anemia.


Assuntos
Anemia/terapia , Falência Renal Crônica/terapia , Assistência Noturna , Satisfação do Paciente , Diálise Renal/métodos , Adulto , Idoso , Anemia/metabolismo , Pressão Sanguínea , Estudos de Casos e Controles , Eritropoetina/sangue , Feminino , Hemoglobinas/metabolismo , Humanos , Hiperfosfatemia/tratamento farmacológico , Hiperfosfatemia/metabolismo , Falência Renal Crônica/metabolismo , Masculino , Pessoa de Meia-Idade , Fosfatos/sangue , Ureia/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA